A combination claim has two parts: the mixture should improve an outcome, and the contribution of combining its components should be understood. Showing that a mixture differs from no treatment answers only the first, and even that answer depends on the quality of the experiment.

A useful design specifies the hypothesis before data collection. Does the combination aim to improve efficacy, reduce an adverse effect or reach a different biological target? Each purpose calls for different measurements. A vague goal such as enhanced recovery makes it difficult to know what result would count as success or failure.

Appropriate component controls help distinguish an added benefit from the effect of a single active ingredient. The analysis should also define how an interaction will be evaluated. A result larger than either component alone is not automatically evidence of synergy under every scientific definition.

The formulation needs its own characterization. Analytical selectivity is important when multiple substances and their impurities coexist; Q2(R2) describes principles for demonstrating that a method measures what it intends to measure. FDA: Q2(R2), validation of analytical procedures Testing the ingredients separately cannot establish every property of the mixture.

Clinical combination research must additionally consider harms and attribution. If a participant develops an adverse event, a multi-agent intervention can make the cause harder to identify. The October 2026 HHS policy's single-API condition reinforces that its described discretion should not be used to imply support for arbitrary stacks. HHS draft 503A peptide policy and appendices

This article is a study-design framework, not a stacking plan. It provides no selected compounds, ratios or administration instructions. A credible combination claim requires a defined formulation, appropriate comparisons, a prespecified analysis and evidence that any added benefit justifies added uncertainty or risk.